Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636153 | 0.88 | L3MBTL1 (0.41) | PTGDR2AKR1B1CYP2C9LMNAKMT2A | |
| SCHEMBL4635855 | 0.85 | PTGDR2 (0.53) | PTGDR2 | |
| SCHEMBL4635707 | 0.85 | PTGDR2 (0.43) | PTGDR2AKR1B1CYP2C9MEN1LMNA | |
| SCHEMBL4636887 | 0.85 | PTGDR2 (0.43) | PTGDR2AKR1B1CYP2C9MEN1LMNA | |
| SCHEMBL4635560 | 0.84 | PTGDR2 (0.46) | PTGDR2AKR1B1CYP2C9MEN1LMNA | |
| SCHEMBL27722499 | 0.83 | PTGDR2 (0.43) | PTGDR2AKR1B1CYP2C9MEN1KMT2A | |
| SCHEMBL2768893 | 0.81 | PTGDR2 (0.50) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL27722500 | 0.76 | PTGDR2 (0.39) | PTGDR2AKR1B1CYP2C9MEN1LMNA | |
| SCHEMBL4636889 | 0.76 | MEN1 (0.35) | PTGDR2AKR1B1CYP2C9MEN1LMNA | |
| SCHEMBL4635708 | 0.76 | PTGDR2 (0.44) | PTGDR2AKR1B1CYP2C9MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1931663-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | Argenta Discovery Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031747-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031747-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | HRH4, HRH2, HRH3 | PTGDR2 293/4885AKR1B1 1414/4885CYP2C9 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.